Key terms
About VYNE
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Bridgewater, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VYNE news
Mar 03
1:01am ET
Vyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
Mar 01
5:18pm ET
VYNE Therapeutics files $250M mixed securities shelf
Feb 29
3:25pm ET
Buy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developments
Feb 29
11:01am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), VYNE Therapeutics (VYNE) and Ironwood Pharma (IRWD)
Feb 29
8:07am ET
VYNE Therapeutics expects cash to fund operations through 2025
Feb 29
8:06am ET
VYNE Therapeutics reports Q4 EPS (20c) vs. ($2.60) last year
Jan 10
10:35am ET
Buy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Results
Jan 10
8:03am ET
VYNE Therapeutics announces biomarker data from Phase 1b trial of VYN201
Jan 03
8:13am ET
VYNE Therapeutics appoints Borowski to board of directors
No recent press releases are available for VYNE
VYNE Financials
Key terms
Ad Feedback
VYNE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VYNE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
